These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 10468696)
61. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. George AM; Meyers NL; Hickling RI Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648 [TBL] [Abstract][Full Text] [Related]
62. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817 [TBL] [Abstract][Full Text] [Related]
63. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Fayyaz M; Lackner JM Ther Clin Risk Manag; 2008 Feb; 4(1):41-8. PubMed ID: 18728719 [TBL] [Abstract][Full Text] [Related]
64. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. Qi Q; Zhang Y; Chen F; Zuo X; Li Y BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568 [TBL] [Abstract][Full Text] [Related]
65. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942 [TBL] [Abstract][Full Text] [Related]
66. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA; Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574 [TBL] [Abstract][Full Text] [Related]
67. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837 [TBL] [Abstract][Full Text] [Related]
68. Tegaserod and other serotonergic agents: what is the evidence? Chey WD Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001 [TBL] [Abstract][Full Text] [Related]
69. Ischemic colitis during treatment with alosetron. Friedel D; Thomas R; Fisher RS Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896 [TBL] [Abstract][Full Text] [Related]
70. Alosetron (Lotronex) for treatment of irritable bowel syndrome. Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030 [No Abstract] [Full Text] [Related]
71. Effects of oral cisapride on small bowel motility in irritable bowel syndrome. Evans PR; Bak YT; Kellow JE Aliment Pharmacol Ther; 1997 Oct; 11(5):837-44. PubMed ID: 9354190 [TBL] [Abstract][Full Text] [Related]
72. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028 [TBL] [Abstract][Full Text] [Related]
73. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Glende M; Morselli-Labate AM; Battaglia G; Evangelista S Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954 [TBL] [Abstract][Full Text] [Related]
74. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635 [TBL] [Abstract][Full Text] [Related]
75. Alosetron in irritable bowel syndrome. McColl KE Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271 [No Abstract] [Full Text] [Related]
76. Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. Spiegel DR; Kolb R Clin Neuropharmacol; 2011; 34(1):36-8. PubMed ID: 21242743 [TBL] [Abstract][Full Text] [Related]
77. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882 [TBL] [Abstract][Full Text] [Related]
78. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Houghton LA; Jackson NA; Whorwell PJ; Cooper SM Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599 [TBL] [Abstract][Full Text] [Related]
79. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177 [TBL] [Abstract][Full Text] [Related]
80. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]